BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic
CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
- CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
- "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
- is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
- BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.